04685cam a2200577Ma 4500 ocn842412695 OCoLC 20171106115917.0 m o d cr |n||||||||a 110329s2013 gw fo 000 0 eng d 9783527669417 (electronic bk.) 3527669418 (electronic bk.) 9781299448902 (MyiLibrary) 1299448909 (MyiLibrary) 9783527322831 (Cloth) 3527322833 (Cloth) AU@ 000051629414 CHBIS 010026923 CHVBK 30623761X DEBBG BV043395820 GBVCP 790207273 NZ1 15340137 NZ1 15905464 (OCoLC)842412695 476140 MIL CDX eng pn CDX DG1 YDXCP NOC OCLCQ OCLCO OCLCF OCLCQ EBLCP MAIN RM301.4 QV 38 615.1/9 22 Modern biopharmaceuticals : recent success stories / edited by Jorg Knablein. [electronic resource] Weinheim : Wiley-VCH Verlag GmbH, 2013. 1 online resource (450 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Related Titles; Title Page; Copyright; Dedication; Foreword by Andreas Busch; Foreword by Günter Stock; Preface; Quotes; List of Contributors; Part I: Modern Biopharmaceuticals: Research is the Best Medicine -- Sanitas Summum Bonus; Chapter 1: Twenty Thousand Years of Biotech -- From "Traditional" to "Modern Biotechnology"; 1.1 Biotechnology -- The Science Creating Life; 1.2 The Inauguration of Biotechnology; 1.3 From "Traditional" to "Modern Biotechnology"; 1.4 A Small Molecule from Bacteria -- A Huge Importance for Mankind; 1.5 Biopharmaceuticals -- The Mainstay of Modern Biotechnology 1.6 Transformation of the Pharma Industry Through Biotechnology1.7 Biopharmaceutical Production -- Uncorking Bottlenecks or Wasting Surplus Capacity?; 1.8 Conclusion and Outlook; References; Part II: Modern Biopharmaceutical Development Using Stem Cells, Tissues, and Whole Animals; Chapter 2: Induced Pluripotency as Substitute of Somatic Cell Nuclear Transfer? -- The Impact of Induced Pluripotent Stem Cells on Drug Discovery and Regenerative Biopharmaceuticals; 2.1 Introduction; 2.2 Derivation and Growth of hESC; 2.3 Signaling Pathways and Transcription Factors 2.4 Differentiation and Applications of hESC2.5 Patient-Specific Nuclear Transfer Stem Cells; 2.6 Patient-Specific Pluripotent Cells Through Direct Reprogramming of Adult Somatic Cells; 2.7 Concluding Remarks and Outlook; Acknowledgment; References; Chapter 3: Pluripotent Stem Cell-Derived Cardiomyocytes for Industrial and Clinical Applications; 3.1 Introduction; 3.2 Pluripotent Stem Cells; 3.3 High-Yield Differentiation of Pluripotent Stem Cells into Cardiomyocytes; 3.4 Purification of Pluripotent Stem Cell-Derived Cardiomyocytes; 3.5 Cardiomyocytes at an Industrial Scale 3.6 Utilization of Tissue Engineering Technologies to Advance Cellular Maturity3.7 Concluding Remarks; References; Chapter 4: Industrialization of Functional Mouse Genomics Technologies for Biopharmaceutical Drug Discovery and Development; 4.1 Introduction; 4.2 The Mouse Genetics Story; 4.3 Establishing Inducible Gene Targeting Tools; 4.4 RNAi -- Talking About a Revolution?; 4.5 Further Shortening the Generation Timeline for RNAi Mouse Models; 4.6 Adapting the Mouse Genetics Toolbox for New Applications; References; Part III: Innovative Development Tools for Modern Biopharmaceuticals Chapter 5: Standardized Solutions for Quantitative and Real-Time RT-PCR to Accelerate Biopharmaceutical Development5.1 Introduction; 5.2 Potential of Real-Time RT-PCR in Biopharmaceutical Development; 5.3 Accurate Gene Expression Analysis Depends on Standardized Preanalytical Steps; 5.4 Accuracy of Real-Time RT-PCR Depends on Efficient cDNA Synthesis; 5.5 Integration of Preanalytical Steps Streamlines Gene Expression Analysis; 5.6 Overview of Methods for Real-Time RT-PCR; 5.7 Developments in Real-Time PCR Instrumentation; 5.8 The Need for Better Standardization of Quantification Methods Print version record. Biopharmaceutics. Biopharmaceutics. fast (OCoLC)fst00832650 Electronic books. Knäblein, Jörg. Print version: 9781299448902 http://onlinelibrary.wiley.com/book/10.1002/9783527669417 Wiley Online Library ddc BK 206708 206708